Phase 2 study of BHV-1300 Graves' Disease and Rheumatoid Arthritis
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs BHV-1300 (Primary)
- Indications Graves' disease; Rheumatoid arthritis
- Focus Therapeutic Use
- 20 Jan 2025 New trial record
- 13 Jan 2025 According to Biohaven Pharmaceuticals media release, company plans to initiate Phase 2 trial to initiate mid-year.